Methods for Improving Cognitive Function Using ILC2 Cranium Implants

ChangeBridge: Patent Apps - Biotech (C12N)

Published April 2nd, 2026

Detected April 2nd, 2026

Summary

The USPTO published patent application US20260091063A1 by Albany Medical College covering methods to improve cognitive function by implanting activated group-2 innate lymphoid cells (ILC2) into a subject's cranium. The application also discloses methods using cytokines including IL-33, IL-5, IL-7, IL-25, and thymic stromal lymphopoietin to treat aging-associated cognitive decline. Assignee: Albany Medical College; Inventors: Qi Yang; Application No. 19335390.

View original document View source feed page

What changed

The USPTO published a patent application disclosing methods for improving cognitive function through intracranial implantation of ILC2 cells pre-treated with an ILC2 activator. The application also covers selecting subjects with aging-associated cognitive decline and administering specific cytokines (IL-33, IL-5, IL-7, IL-25, TSLP) to promote innate lymphoid cell activity. CPC classifications span cellular therapies, immunological compositions, and neurological indications (A61P 25/28).

Patent applicants and researchers in cellular therapy, immunotherapy, and neurological treatments may consider this publication when evaluating freedom-to-operate, prior art, or research directions. The publication date is April 2, 2026; the filing date was September 22, 2025. No compliance actions or deadlines are associated with this publication. Companies developing cell-based or cytokine-based cognitive therapies should monitor this application for potential competitive implications.

Source document (simplified)

← USPTO Patent Applications

METHODS FOR IMPROVING COGNITIVE FUNCTION

Application US20260091063A1 Kind: A1 Apr 02, 2026

Assignee

ALBANY MEDICAL COLLEGE

Inventors

Qi YANG

Abstract

The present disclosure relates to a method of improving cognitive function in a subject. The method includes implanting group-2 innate lymphoid cells (ILC2) in a cranium of a subject, where the ILC2 was treated with an ILC2 activator. The present disclosure further relates to a method including selecting a subject having aging-associated cognitive decline and administering to the subject an activator of innate lymphoid cell activity under conditions effective to promote innate lymphoid cell activity. The present disclosure further relates to a method of improving cognition in a subject. The method includes selecting a subject having aging-associated cognitive decline and administering to the subject a cytokine selected from the group consisting of IL-33, IL-5, IL-7, IL-25, and thymic stromal lymphopoietin.

CPC Classifications

A61K 35/26 A61K 9/0024 A61K 31/202 A61K 31/5575 A61K 35/17 A61K 35/741 A61K 38/19 A61K 38/20 A61K 38/2033 A61K 38/2046 A61K 39/3955 A61P 25/28 C12N 5/0634